Rimegepant — Membership Pricing

Other medications in Neurological

• Risdiplam
• Rivastigmine
• Rizatriptan
• Ropinirole
• Rufinamide
• Selegiline
• Siponimod
• Sumatriptan

About Rimegepant

Rimegepant offers a significant advancement for migraine sufferers, providing both acute and preventive treatment in one medication. Understanding your options and managing costs are key to consistent care. At TheDrugClub, we're committed to helping our members navigate prescription expenses, offering valuable savings on medications like rimegepant to make effective migraine relief more attainable.

What is Rimegepant and What Does it Treat?

Rimegepant, known by its brand name Nurtec ODT, is an innovative prescription medication specifically designed to treat migraine headaches in adults. Its unique advantage lies in its dual capability: it can be taken to stop a migraine attack *after* it has started (acute treatment) and also to *prevent* future migraine episodes from occurring. This dual action makes it a versatile tool in a comprehensive migraine management plan, offering flexibility that many other migraine medications lack.

How Does Rimegepant Work?

Rimegepant belongs to a class of drugs called calcitonin gene-related peptide (CGRP) receptor antagonists. Migraine attacks are often associated with the release of CGRP, a neuropeptide that plays a crucial role in transmitting pain signals and causing blood vessels to dilate in the brain. By blocking the CGRP receptor, rimegepant prevents CGRP from binding and activating these pain pathways. This mechanism helps to alleviate the symptoms of an acute migraine and, when taken regularly, can reduce the frequency of migraine attacks, offering a different approach compared to traditional triptans or older preventive therapies.

Typical Costs of Rimegepant

As a newer, brand-name medication, rimegepant can carry a significant price tag, especially without insurance coverage. The cost can vary widely depending on factors such as your insurance plan, the specific pharmacy you use, the dosage prescribed, and your geographic location. Without insurance, a single prescription (e.g., for 8 or 16 oral dissolving tablets) could range from several hundred to over a thousand dollars. It

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Rimegepant is approved for (FDA label)

NURTEC ODT is a calcitonin gene-related peptide receptor antagonist indicated for the: • acute treatment of migraine with or without aura in adults ( 1.1 ) • preventive treatment of episodic migraine in adults ( 1.2 ) 1.1 Acute Treatment of Migraine NURTEC ODT is indicated for the acute treatment of migraine with or without aura in adults . 1.2 Preventive Treatment of Episodic Migraine NURTEC ODT is indicated for the preventive treatment of episodic migraine in adults.

Source: Read the full FDA label on DailyMed. Label effective date: June 4, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Rimegepant (FDA label)

Orally disintegrating tablets: white to off-white, circular, and debossed with the symbol , each containing 75 mg of rimegepant. NURTEC ODT orally disintegrating tablets: 75 mg ( 3 ) Image

Source: FDA prescribing information (DailyMed). Set ID: 9ef08e09-1098-35cc-e053-2a95a90a3e1d. SPL document ID: c044a03c-e8ff-4a75-9146-69f9cf50f79d. Label effective date: June 4, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Rimegepant (FDA label)

The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling: • Hypersensitivity Reactions [see Warnings and Precautions (5.1) ] • Hypertension [see Warnings and Precautions (5.2) ] • Raynaud’s Phenomenon [see Warnings and Precautions (5.3) ] • Acute treatment of migraine: the adverse reaction reported in ≥1% of patients treated with NURTEC ODT is nausea. ( 6.1 ) • Preventive treatment of episodic migraine: adverse reactions reported in ≥2% for rimegepant and ≥1% higher than placebo are nausea and abdominal pain/dyspepsia. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. Acute Treatment of Migraine The safety of NURTEC ODT for the acute treatment of migraine in adults has been evaluated in a randomized, double-blind, placebo-controlled trial (Study 1) in 682 patients with migraine who received one 75 mg dose of NURTEC ODT [see Clinical Studies (14) ] . Approximately 85% were female, 74% were White, 21% were Black, and 17% were Hispanic or Latino. The mean age at study entry was 40 years (range 18-75 years of age). Long-term safety was assessed in an open-label extension study using a different oral dosage form of rimegepant. That study evaluated 1,798 patients, dosing intermittently for up to one year, including 1,131 patients who were exposed to rimegepant 75 mg for at least 6 months, and 863 who were exposed for at least one year, all of whom treated an average of at least two migraine attacks per month. The most common adverse reaction in Study 1 was nausea (2% in patients who received NURTEC ODT compared to 0.4% of patients who received placebo).

Source: FDA prescribing information (DailyMed). Set ID: 9ef08e09-1098-35cc-e053-2a95a90a3e1d. SPL document ID: c044a03c-e8ff-4a75-9146-69f9cf50f79d. Label effective date: June 4, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Rimegepant (FDA label)

NURTEC ODT is contraindicated in patients with a history of hypersensitivity reaction to rimegepant, NURTEC ODT, or any of its components. Reactions have included anaphylaxis and delayed serious hypersensitivity [see Warnings and Precautions (5.1) ] . Patients with a history of hypersensitivity reaction to rimegepant, NURTEC ODT, or to any of its components. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 9ef08e09-1098-35cc-e053-2a95a90a3e1d. SPL document ID: c044a03c-e8ff-4a75-9146-69f9cf50f79d. Label effective date: June 4, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Rimegepant (FDA label)

• Hypersensitivity Reactions: If a serious hypersensitivity reaction occurs, discontinue NURTEC ODT and initiate appropriate therapy. Severe hypersensitivity reactions have included anaphylaxis, dyspnea, and rash, and can occur days after administration. ( 5.1 ) • Hypertension: New-onset or worsening of pre-existing hypertension may occur. ( 5.2 ) • Raynaud’s Phenomenon: New-onset or worsening of pre-existing Raynaud’s phenomenon may occur. ( 5.3 ) 5.1 Hypersensitivity Reactions Serious hypersensitivity reactions, including anaphylaxis, dyspnea , and rash, have occurred in patients treated with NURTEC ODT . Hypersensitivity reactions can occur days after administration, and delayed serious hypersensitivity has occurred. If a hypersensitivity reaction occurs, discontinue NURTEC ODT and initiate appropriate therapy [see Contraindications (4) and Adverse Reactions (6.1 , 6.2) ] . 5.2 Hypertension Development of hypertension and worsening of pre-existing hypertension have been reported following the use of CGRP antagonists, including NURTEC ODT, in the postmarketing setting.

Source: FDA prescribing information (DailyMed). Set ID: 9ef08e09-1098-35cc-e053-2a95a90a3e1d. SPL document ID: c044a03c-e8ff-4a75-9146-69f9cf50f79d. Label effective date: June 4, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Rimegepant (FDA label)

• Strong CYP3A4 Inhibitors: Avoid concomitant administration. ( 7.1 ) • Moderate CYP3A4 Inhibitors: Avoid another dose within 48 hours when administered with a moderate CYP3A4 inhibitor. ( 7.1 ) • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. ( 7.2 ) • Potent Inhibitors of P-gp: Avoid another dose of NURTEC ODT within 48 hours when administered with a potent P-gp inhibitor. ( 7.3 ) 7.1 CYP3A4 Inhibitors Concomitant administration of NURTEC ODT with strong inhibitors of CYP3A4 results in a significant increase in rimegepant exposure. Avoid concomitant administration of NURTEC ODT with strong inhibitors of CYP3A4 [see Clinical Pharmacology (12.3) ] . Concomitant administration of NURTEC ODT with moderate inhibitors of CYP3A4 may result in increased exposure of rimegepant.

Source: FDA prescribing information (DailyMed). Set ID: 9ef08e09-1098-35cc-e053-2a95a90a3e1d. SPL document ID: c044a03c-e8ff-4a75-9146-69f9cf50f79d. Label effective date: June 4, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.